PermaLink; Antibody Drug Conjugate (ADC) conjugation platform technology

  • Technology Overview: Novel conjugation platform for ADCs (Antibody Drug Conjugates)
  • Primary Application: Development of next-generation biotherapeutics for cancer
  • Secondary Applications: Conjugate Vaccines, Albumin Conjugates
  • Core Differentiators:
    1. Unique, patented chemistry approach
    2. High specificity for cysteine binding
    3. Market leading conjugation stability
    4. Enhanced ADC stability vs on-market conjugation approaches
    5. Associated with ADCs of enhanced therapeutic index
  • Development Stage: PreClinical
  • Opportunity: Available for license and sponsored research